Population and sampling Sample Clauses

Population and sampling. The deregulation of local telecommunication began at the state level before it was mandated nationally with the Telecom Act; in Georgia, it began in 1995, which is the first year of my sampling timeframe. Figure 4 shows that between 1995 and 2007, 492 entrepreneurs initiated the CLEC certification process in Georgia, as measured by their submitting paperwork to the PSC. Of these 492, 74 (15%) voluntarily withdrew their application prior to its approval by the PSC. Only 12 of the 492 (2%) had their application denied. Thus, unlike many studies of entrepreneurship, there appears to be little left truncation of individuals who desired to become CLECs but did not show up in the data set. The remaining 406 firms (83%) comprise the sample population of CLECs that became certified in Georgia during the sample timeframe. Figure 4: Outcomes of 492 requests initiated for CLEC certification in Georgia Withdrawn 74 (15%) Denied 12 (2%) Approved 406 (83%) Of the 406 ventures that became certified as CLECs in Georgia, 80% of these, or 321 are the primary focus of my analysis. This excludes from the sample 22 local municipalities that formed CLEC entities (6%); as noted before, such organizations have features that are atypical to new ventures. As well, analyses revealed only one failure among the entire sample of municipalities which, together with their unique structural features, could bias the results. I also excluded 33 solo founders (8%), which could misrepresent the team effects in which I was interested. Later robustness tests evaluate tests of the hypotheses results when solo founders are included; such tests show their exclusion to have minimal influence on the final results. As well, I was unable to use the data on an additional 30 firms; 26 of these founders (6%) filed their financials as Trade Secret, such that I had no measures of their initial startup capital. The other 4 firms (1%) had missing data on the experience of the founding team. Figure 5 illustrates this breakdown. Of the 321 new CLEC ventures that comprise the primary sample population for hypothesis testing (79%), 167 were resellers (52%) and 142 were facilities-based providers (48%). Figure 5: Exclusions of certified CLECs (n=406) from final sample Trade secret Muni's 22 (6%) Missing 4 (1%) 26 (6%) Solo Final founders 33 (8%) sample 321 (79%) Although CLECs required certification in each state where they operated, not all state-by- state data were comparable. I therefore limited my focus to CL...
AutoNDA by SimpleDocs
Population and sampling. Population is a full set of cases from which a sample is obtained for analysis (Xxxxxxxx et al., 2009). Within the framework of this study, purposeful sampling was used in order to explore and understand the central phenomenon. Purposeful sampling is a type of sampling where the researcher deliberately chooses individuals and sites that are found to be “information-rich” (Xxxxxxxx, 2014). In the present study, the following criteria was assigned to participants recruited for this study: the research site was secondary schools within Kisumu County and not primary schools because several scholars have conducted studies about teacher attitudes on primary school, for example, a study was conducted in Siaya County primary schools to establish the extent to which teachers had implemented inclusive education practices (Oracha, 2018). Kisumu County is rich in diversity because it comprises of schools situated in both urban and rural settings that gave a variety of experiences by the school principals. This gave me an opportunity to explore the experiences of principals dealing with learners and parents from diverse backgrounds. Several studies have also been conducted on teacher attitudes (Xxxxx et al. 2020.; Xxxxxx & Xxxxxxxx, 2016), but little on secondary school principals thus the reason to pick principals as the key respondents during this study. Principals are school leaders who are among major decision makers on school matters and therefore their knowledge of IE should be sought. They were principals having nearly similar demographic background such as having more than six years in administrative position and having at least one inclusive student. This was achieved by contacting Kisumu County Teachers Service Commissioner to inquire how many schools are present in the County and then placed a request on the principals contact details especially those who have worked in the same position for more than six years. Xxxxxxxx (2014) describes several sampling strategies that can be used either before the data collection starts or after data collection has begun. In this sense, criterion sampling form of purposeful sampling was used to select six principals as the number is manageable especially during these fragile moments of the Covid-19 pandemic. Purposeful sampling is sometimes referred to as judgmental sampling because it occurs when the researcher has knowledge of the participants and some of the expected characteristics. Some of this information was obtaine...
Population and sampling. Participants for the study were initially recruited from a local non-profit in the Metro Atlanta area that teaches leadership and life skills to African American (AA) teen girls. Verbal consent was initially sought from the parents in order to allow the girls to participate in the study. Additionally, verbal assent was gathered from the girls. A time and place to conduct the study was established (typically the participant’s home), and signed informed consent and assent forms were required before initiation. All participants were given a $5 cash incentive for participation in the study. The chain sampling method was used to identify other AA teenagers who might be interested in participating; participants and their parents offered names and contact information to reach other AA teenagers. Girls were permitted to participate in the study based on their willingness, age (13-18 years), and self-identification as both “African American” and “female”. Chain sampling was continued until the study was able to sufficiently reach saturation. Saturation was reached after recruiting and interviewing 24 participants from January to March 2019. Each interview lasted approximately 44 minutes. Consent Informed consent forms were provided to participants and their parents. Assent forms were given to teenagers from 13-17 years of age. The forms contained an overview of the study, procedures, risks, benefits, confidentiality, and the researcher’s contact information. Consent was obtained directly from teenagers who were 18-years-old. Parents consented for their daughters who were under age 18. Before the study began, participants and parents were allowed to ask clarifying questions. The researcher also reiterated that participants were free to withdraw from the study or refuse any procedures without fear of penalty, including that they would not forfeit their $5 cash incentive for ending the study early.
Population and sampling. The samples included registered nurses currently practicing in university hospitals in Yunnan Province with at least one year of nursing experience. The sample size of 378 was calculated based on the Yamane (1967) formu- la. Taking into consideration the possible loss of nurses, 10% of the sample was added (Burns & Grove, 2005).

Related to Population and sampling

  • Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: minimum 21 days/3 weeksuntil patient's weight >2000g, averaged 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months following enterostomy closure (12- month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 months of overall study duration).

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Inspection and Testing Each Constructing Entity shall cause inspection and testing of the Interconnection Facilities that it constructs in accordance with the provisions of this section. The Construction Parties acknowledge and agree that inspection and testing of facilities may be undertaken as facilities are completed and need not await completion of all of the facilities that a Constructing Entity is building.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!